Abstract
This dataset provides an overview of the baseline demographic characteristics of patients with advanced solid tumors who participated in the ongoing phase 1 trial of botensilimab. This demographic information is crucial for understanding the patient population studied and is valuable for interpreting the safety and efficacy outcomes of the study.